Loading…
Zhejiang pharma maker specializing in central-nervous-system generics such as sedatives and antidepressants, plus APIs.
Zhejiang pharma maker specializing in central-nervous-system generics such as sedatives and antidepressants, plus APIs.
Sells generic drugs mainly to hospitals, where volume is won by bidding in government-run purchasing programmes in which lower bids win larger orders, so scale and cost control matter more than pricing power. Central-nervous-system drugs carry the range, and active ingredients sold to other drugmakers add a smaller business.
In one line: A Chinese generics maker focused on CNS drugs.
Moat: none (scale). Generic manufacturer competing on tender price rather than proprietary products.
Headquarters: Shaoxing, Zhejiang, China · Employees: 3,732
Size Zhejiang Jingxin Pharmaceutical (002020.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.49B, the 1644th largest of 4,839 China companies the cockpit tracks. Shares closed at CN¥12.31 on 6 Nov 2026.
Performance Over six months the shares fell 16.7%, against -10.8% for the median peer and -16.4% for the China market (cap-weighted) — 11th highest of 21 in its peer set.
Growth Revenue grew 1.5% over the last twelve months (peer median +4.9%); the operating margin is 18.6% (peer median -10.3%).
Valuation It trades at 13.0× forward earnings against a peer median of 28.2× (3rd cheapest of 11).
Price implies For today's price to make sense, revenue must grow about -8% a year for seven years (Req g). Recent delivered growth is +5%, so the hurdle is -13 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 8.5 points above its cost of capital (5.0% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | CN¥4.06B | CN¥4.05B | CN¥4.14B | CN¥3.98B | CN¥3.76B |
| Revenue growth | — | -2% | +4% | +6% | — |
| Gross profit | CN¥2.22B | CN¥1.94B | CN¥1.97B | CN¥1.93B | CN¥1.90B |
| EBITDA | n/a | CN¥1.06B | CN¥1.02B | CN¥801M | CN¥818M |
| Net income | CN¥709M | CN¥758M | CN¥712M | CN¥619M | CN¥662M |
| Free cash flow | CN¥810M | CN¥606M | CN¥538M | CN¥305M | CN¥459M |
| Capital expenditure | CN¥196M | CN¥203M | CN¥251M | CN¥520M | CN¥516M |
| Total debt | CN¥524M | CN¥484M | CN¥603M | CN¥652M | CN¥640M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Zhejiang Jingxin Pharmaceutical 002020.SZ | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% |
| Jiangsu Hengrui Pharmaceuticals 600276.SS | $49.7B | -6% | +6% | 27% | 36.4× | 14.9% |
| Livzon Pharmaceutical 000513.SZ | $3.71B | -4% | -14% | 19% | 16.9× | -9.8% |
| Zhejiang Huahai Pharmaceutical 600521.SS | $3.86B | +8% | +10% | 12% | 22.1× | 7.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 002020.SZ | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +5.2% | -0.9% | 7th highest of 21 |
| 6-month return | -16.7% | -10.8% | 11th highest of 21 |
| Distance from 52-week high | -43.1% | -35.8% | 10th lowest of 21 |
| Revenue growth (TTM) | +1.5% | +4.9% | 8th lowest of 19 |
| Operating margin | 18.6% | -10.3% | 2nd highest of 19 |
| Forward P/E | 13.0× | 28.2× | 3rd cheapest of 11 |
| Growth the price implies (Req g, 7 yrs) | -8.5% | 29.6% | 2nd least demanding of 8 |
| Growth delivered (Del g) | +4.6% | +11.1% | 3rd lowest of 8 |
| Hurdle (Req g minus delivered) | -13.1 pp | +3.8 pp | 2nd least demanding of 8 |
| ROIC minus cost of capital | +8.5 pp | -6.6 pp | 2nd highest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Zhejiang Jingxin Pharmaceutical 002020.SZ | China | $1.49B | -17% | +1% | 19% | 13.0× | -8.5% | +4.6% |
| ABL Bio 298380.KS | South Korea | $1.49B | -73% | -64% | -251% | n/a | n/a | n/a |
| Damora Therapeutics DMRA | United States | $1.46B | -2% | n/a | n/a | n/a | n/a | n/a |
| Ultragenyx Pharmaceutical RARE | United States | $1.52B | +22% | +16% | -64% | n/a | n/a | n/a |
| Guangdong Taienkang Pharmaceutical 301263.SZ | China | $1.53B | -17% | +2% | -2% | 42.9× | n/a | n/a |
| Marksans Pharma MARKSANS.NS | India | $1.45B | +50% | +24% | 20% | 24.2× | 31.6% | +16.6% |
| Pacira Biosciences PCRX | United States | $1.45B | +57% | +6% | 4% | 11.8× | 14.9% | +11.1% |
| Structure Therapeutics, Inc. Sponsored ADR GPCR | United States | $1.45B | -48% | n/a | n/a | n/a | n/a | n/a |
| Ocular Therapeutix OCUL | United States | $1.45B | -32% | -8% | -603% | n/a | n/a | n/a |
| Nanobiotix NANO.PA | France | $1.54B | -42% | -77% | -392% | n/a | n/a | n/a |
| Chongqing Lummy Pharmaceutical 300006.SZ | China | $1.55B | +53% | -6% | -19% | n/a | 49.9% | -13.2% |
| Mabwell (Shanghai) Bioscience 688062.SS | China | $1.44B | -38% | +15% | -129% | n/a | n/a | n/a |
| Indegene INDGN.NS | India | $1.56B | +15% | +36% | 12% | 27.5× | 29.6% | +29.4% |
| Nippon Shinyaku 4516.T | Japan | $1.43B | -30% | +12% | 19% | 7.7× | -17.5% | +7.0% |
| Zhejiang CONBA Pharmaceutical 600572.SS | China | $1.56B | -5% | +4% | 9% | 18.5× | -5.8% | +1.9% |
| Mezzion Pharma 140410.KS | South Korea | $1.42B | -29% | +7% | -223% | n/a | n/a | n/a |
| Corona Remedies CORONA.NS | India | $1.58B | +40% | +17% | 18% | 63.7× | 37.6% | +16.6% |
| Xiamen Kingdomway 002626.SZ | China | $1.58B | +15% | -3% | 11% | 30.0× | n/a | n/a |
| Staidson (Beijing) Biopharmaceuticals 300204.SZ | China | $1.41B | -36% | -24% | -51% | 585.0× | n/a | n/a |
| Jubilant Pharmova JUBLPHARMA.NS | India | $1.58B | -4% | +16% | 9% | 29.0× | n/a | n/a |
| LigaChem Biosciences 141080.KS | South Korea | $1.59B | -68% | -33% | -208% | n/a | n/a | n/a |